Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Core Viewpoint - Cytek Biosciences, Inc. will report its financial results for Q4 and full year 2025 on February 26, 2026, with a conference call to discuss the results and outlook [1]. Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution, high-content, and high-sensitivity cell analysis [2]. - The company's product offerings include core FSP instruments such as Cytek Aurora™, Northern Lights™, and Cytek Aurora™ Evo systems, as well as the Cytek Orion™ reagent cocktail preparation system and Enhanced Small Particle™ (ESP™) detection technology [2]. - Cytek is headquartered in Fremont, California, and has a global presence with offices and distribution channels [2]. Product Usage - Cytek's products are intended for research use only, with the exception of the Northern Lights-CLC system and certain reagents available for clinical use in China and the European Union [3]. Information Distribution - Cytek utilizes various channels, including its website, LinkedIn page, and X account, to distribute information about the company, products, and financial announcements, complying with Regulation FD [4].